blood-based biomarkers relevant to the Alzheimer's Association recommended guidelines: brain-derived phosphorylated tau 217 (BD-pTau217), neurofilament light chain (NfL), amyloid-beta 42 (Aβ42), glial fibrillary acidic protein (GFAP), and APOE4...
from the combined Phase 3 SPOTLIGHT (NCT03504397) and GLOW (NCT03653507) studies in patients with HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction. (GEJ) adenocarcinoma in ESMO Open, characterizing the management of...
waste management. Millions of Americans rely on self-administered injectable medications every day, including insulin, GLP-1 therapies, migraine biologics, and autoimmune biologics. The resulting waste (billions of discarded needles and syringes)...
that enrollment of the first participants has been completed in a Phase 2 clinical trial in Australia evaluating SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) protein-based vaccine candidates based on prefusion-stabilized F (PreF)-Trimer...
for Reconstitution, for fibrinogen replacement in patients with acquired fibrinogen deficiency (AFD). This new kit includes 100 mL of Water for Infusion (WFI) and continues to feature the nextaro® reconstitution device, offering enhanced...
tract, supporting sustained therapeutic exposure throughout the day. Aizhida was approved by the U.S. FDA in March 2021 as a once-daily treatment option for patients with ADHD 6 years of age and older. ADHD is a common, chronic neurodevelopmental...
brings nearly three decades of experience in the global CRO industry and has served as Novotech Chairman since 2021. He commenced as Chairman and CEO on 1 January 2026. Reflecting Novotech’s increasingly international profile, Dr. Tharmaratnam will...
Measures MOCA (Montreal Cognitive Assessment) scores remained unchanged at week 22, compared to baseline (Baseline, 13.5 and week 22, 14) suggesting no decline in cognitive function over the 22-week period. CDR-FTLD scores did not significantly...
diseases, announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service...
the next generation of degrader antibody conjugates (DACs) for oncology and beyond. The company is advancing its GSPT1-directed TPD² programs and developing novel degrader payloads to expand the potential of targeted protein degradation. Orum's...
Bioepis Co., Ltd. announced that the company has begun direct commercialization of BYOOVIZ®, a biosimilar to Lucentis1 (ranibizumab), in Europe. Samsung Bioepis has been working to ensure seamless transfer of commercial rights from Biogen back to...
neuromodulation. Systematic variation of stimulation parameters produced dose-dependent changes in alpha-band (8–12 Hz) and gamma-band (78–82 Hz) neural activity, confirming that stimulation reliably modulates physiological signals....
Marcel Jacobs, CEO of Matisse Pharmaceuticals. About Matisse Pharmaceuticals Matisse Pharmaceuticals B.V. was founded in 2014 in Geleen, the Netherlands. Matisse is dedicated to develop a product portfolio of safe and innovative therapies for...
Sapio Sciences, the science-awareTM AI lab informatics platform, announced that the Wellcome Sanger Institute has selected the Sapio Informatics Platform as its central LIMS to underpin the Institute’s ambitious lab transformation program. The...
machine learning or AI-driven software without any robotic execution. Bringing a new medicine to market still takes 10-15 years and over $2B because discovery and preclinical work are slow, manual, and fragmented. Pharma has tried to fix this with...
for the treatment of predominantly non-enhancing Grade 2 astrocytoma or oligodendroglioma with an isocitrate dehydrogenase-1 (IDH1) R132 or isocitrate dehydrogenase-2 (IDH2) R172 mutation in adult and adolescent patients aged 12 years and older and...
FIZE Medical Inc., a leader in smart fluid management solutions for critically ill patients, announced an exclusive distribution agreement with Asahi Kasei Medical Co., Ltd. to launch the FIZE kUO® system in Japan. Asahi Kasei Medical, a world...
webinar "Advancing bariatric endoscopy" Join Prof. Ivo Boskoski, MD, Christopher McGowan, MD and Abdullah AlMousa, MD on 11 December for a live online session on the latest developments in bariatric endoscopy and GMA with MOVIVA®: Webinar...
This growth is particularly remarkable considering that Re2O had relatively low brand recognition only six months ago. Dermatology and plastic surgery clinics, as well as major university hospitals across Korea, have recently accelerated adoption...
Celltrion, Inc. announced that Health Canada has approved Eydenzelt®, a biosimilar referencing Eylea® (aflibercept 2mg), in both vial and pre-filled syringe format, for treatment of all indications approved for Eylea. “Today’s approval lays a...